Journal
STEM CELLS
Volume 32, Issue 4, Pages 959-973Publisher
WILEY
DOI: 10.1002/stem.1618
Keywords
Clinical translation; Locked nucleic acid; MicroRNA; Osteosarcoma
Categories
Funding
- Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan (NiBio)
- Ministry of Health, Labor and Welfare of Japan
- Grants-in-Aid for Scientific Research [26293342, 22390296] Funding Source: KAKEN
Ask authors/readers for more resources
Novel strategies against treatment-resistant tumor cells remain a challenging but promising therapeutic approach. Despite accumulated evidence suggesting the presence of highly malignant cell populations within tumors, the unsolved issues such as in vivo targeting and clinical relevance remain. Here, we report a preclinical trial based on the identified molecular mechanisms underlying osteosarcoma-initiating cells and their clinical relevance. We identified key microRNAs (miRNAs) that were deregulated in a highly malignant CD133(high) population and found that miR-133a regulated the cell invasion that characterizes a lethal tumor phenotype. Silencing of miR-133a with locked nucleic acid (LNA) reduced cell invasion of this cell population, and systemic administration of LNA along with chemotherapy suppressed lung metastasis and prolonged the survival of osteosarcoma-bearing mice. Furthermore, in a clinical study, high expression levels of CD133 and miR-133a were significantly correlated with poor prognosis, whereas high expression levels of the four miR-133a target genes were correlated with good prognosis. Overall, silencing of miR-133a with concurrent chemotherapy would represent a novel strategy that targets multiple regulatory pathways associated with metastasis of the malignant cell population within osteosarcoma. Stem Cells 2014;32:959-973
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available